Literature DB >> 9839535

Melatonin administration increases the affinity of D2 dopamine receptors in the rat striatum.

A Hamdi1.   

Abstract

Rats receive melatonin (MEL) (476 +/- 6.5 microg/kg/day) via their drinking water for 2 weeks. At the end of this period, the density of D2 dopamine (DA) receptors and their affinity for [3H]-YM-09151-2 are measured in the striatum. MEL treatment increases the apparent affinity (decreases the Kd) of D2 DA receptors for [3H]YM-09151-2 by 48%, while it does not significantly alter the density (Bmax). These findings indicate that the affinity of D2 DA receptors in the striatum is influenced by exposure to MEL. The possible implications of these results are discussed.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9839535     DOI: 10.1016/s0024-3205(99)80008-3

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  7 in total

1.  Common variants in DRD2 are associated with sleep duration: the CARe consortium.

Authors:  Brian E Cade; Daniel J Gottlieb; Diane S Lauderdale; David A Bennett; Aron S Buchman; Sarah G Buxbaum; Philip L De Jager; Daniel S Evans; Tibor Fülöp; Sina A Gharib; W Craig Johnson; Hyun Kim; Emma K Larkin; Seung Ku Lee; Andrew S Lim; Naresh M Punjabi; Chol Shin; Katie L Stone; Gregory J Tranah; Jia Weng; Kristine Yaffe; Phyllis C Zee; Sanjay R Patel; Xiaofeng Zhu; Susan Redline; Richa Saxena
Journal:  Hum Mol Genet       Date:  2015-10-13       Impact factor: 6.150

2.  Worsening Choreoathetosis in Huntington's Disease with Fluoxetine, Lisdexamfetamine, and Melatonin: A Case Report.

Authors:  Clayton J Hamilton; Tysen K Timmer; Robert C Munjal; Fernando Cardozo-Pelaez; Ian R Mcgrane
Journal:  Innov Clin Neurosci       Date:  2018-08-01

3.  Activation of Melatonin Receptors Reduces Relapse-Like Alcohol Consumption.

Authors:  Valentina Vengeliene; Hamid R Noori; Rainer Spanagel
Journal:  Neuropsychopharmacology       Date:  2015-05-21       Impact factor: 7.853

4.  Effect of chronic L-dopa or melatonin treatments after dopamine deafferentation in rats: dyskinesia, motor performance, and cytological analysis.

Authors:  Ana Luisa Gutierrez-Valdez; Verónica Anaya-Martínez; José Luis Ordoñez-Librado; Ricardo García-Ruiz; Carmen Torres-Esquivel; Montserrat Moreno-Rivera; Javier Sánchez-Betancourt; Enrique Montiel-Flores; Maria Rosa Avila-Costa
Journal:  ISRN Neurol       Date:  2012-02-01

5.  PDK4 Inhibition Ameliorates Melatonin Therapy by Modulating Cerebral Metabolism and Remyelination in an EAE Demyelinating Mouse Model of Multiple Sclerosis.

Authors:  Majid Ghareghani; Zahra Farhadi; Serge Rivest; Kazem Zibara
Journal:  Front Immunol       Date:  2022-03-09       Impact factor: 7.561

Review 6.  Insights into Potential Targets for Therapeutic Intervention in Epilepsy.

Authors:  Cecilia Zavala-Tecuapetla; Manola Cuellar-Herrera; Hiram Luna-Munguia
Journal:  Int J Mol Sci       Date:  2020-11-13       Impact factor: 5.923

Review 7.  The melatonergic system in mood and anxiety disorders and the role of agomelatine: implications for clinical practice.

Authors:  Domenico De Berardis; Stefano Marini; Michele Fornaro; Venkataramanujam Srinivasan; Felice Iasevoli; Carmine Tomasetti; Alessandro Valchera; Giampaolo Perna; Maria-Antonia Quera-Salva; Giovanni Martinotti; Massimo di Giannantonio
Journal:  Int J Mol Sci       Date:  2013-06-13       Impact factor: 5.923

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.